© 2004 European Society for Medical Oncology
Original Article |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
1 University Hospital, Dresden, Germany; 2 Royal-Marsden Hospital, Sutton, UK; 3 University of Uppsala, Akademiska sjukhuset, Uppsala, Sweden; 4 Azienda Ospedale Careggi, Firence, Italy; 5 St Laurentius Hospital, Roermond, The Netherlands; 6 University Medical School, Vienna, Austria; 7 Hospital Ambroise Pare, Boulogne, France; 8 Hospital Clinico Provincial, Cordoba, Spain; 9 Medical School, Hannover, Germany
* Correspondence to:Prof. C.-H. Köhne, University Hospital ‘Carl Gustav Carus’, Medical Department, Fetscherstraße 74, 01307 Dresden, Germany. Tel: +49-351-458-4781; Fax: +49-351-458-5859; Email: claus-henning.koehne{at}uniklinikum-dresden.de
Background: Recently published population-based investigations showed elderly patients to be underrepresented in clinical trials and less often treated according to the standard therapy. Although there is evidence that elderly patients benefit from adjuvant (radio-) chemotherapy to the same extent as younger patients, no large series describes the influence of age on efficacy of chemotherapy in metastatic colorectal cancer.
Patients and methods: We carried out a retrospective analysis using source data of 3825 patients who received 5-fluorouracil (5-FU)-containing treatment in 22 European trials and identified 629 patients with an age of 
70 years.
Results: We found an equal overall survival in elderly patients [10.8 months, 95% confidence interval (CI) 9.7–11.8] and in younger patients (11.3 months, 95% CI 10.9–11.7; P=0.31). Response rate did not differ between age groups 70 and <70 years (23.9% and 21.1%; respectively; P=0.14). Progression-free survival was marginally prolonged in elderly patients (5.5 months, 95% CI 5.2–5.8; compared with 5.3 months, 95% CI 5.1–5.5; P=0.01). In both age groups, infusional 5-FU resulted in significantly increased response rates, overall survival and progression-free survival compared with bolus 5-FU.
Conclusions: ‘Fit’ elderly patients benefit at least to the same extent from palliative chemotherapy with 5-FU as younger patients. Infusional 5-FU was shown to be more effective than bolus 5-FU in both age groups. Therefore, standardized palliative chemotherapy should generally be offered to elderly patients and they should not be excluded from clinical trials.
Key words: 5-FU, chemotherapy, colorectal cancer, elderly patients
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials J. Clin. Oncol., January 10, 2009; 27(2): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., January 1, 2009; 20(1): 5 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ananda, K. M. Field, S. Kosmider, D. Compston, J. Desai, L. C. Lim, F. S. Barnett, I. T. Jones, I. Skinner, and P. Gibbs Patient Age and Comorbidity Are Major Determinants of Adjuvant Chemotherapy Use for Stage III Colon Cancer in Routine Clinical Practice J. Clin. Oncol., September 20, 2008; 26(27): 4516 - 4517. [Full Text] [PDF]
|
|
|
|
 |
|
 T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting Oncologist, August 1, 2008; 13(8): 876 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Field, S. Kosmider, M. Jefford, M. Michael, R. Jennens, M. Green, and P. Gibbs Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey J. Oncol. Pract, May 1, 2008; 4(3): 108 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier Chemotherapy in Elderly Patients with Colorectal Cancer Oncologist, April 1, 2008; 13(4): 390 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, M. T. Seymour, L. Saltz, J.-Y. Douillard, H. Hecker, R. J. Stephens, T. S. Maughan, E. Van Cutsem, P. Rougier, E. Mitry, et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials J. Clin. Oncol., March 20, 2008; 26(9): 1443 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lichtman Pharmacology of Antineoplastic Agents for Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Hochster, W. Luo, E. C. Popa, B. T. Lyman, M. Mulcahy, P. A. Beatty, and A. B. Benson Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (>= 75 years old) Patients With Colorectal Cancer: ECOG 1299 J. Clin. Oncol., December 1, 2007; 25(34): 5397 - 5402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Sanoff, H. Bleiberg, and R. M. Goldberg Managing Older Patients With Colorectal Cancer J. Clin. Oncol., May 10, 2007; 25(14): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Gusella, G Crepaldi, C Barile, A Bononi, D Menon, S Toso, D Scapoli, L Stievano, E Ferrazzi, F Grigoletto, et al. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer Ann. Onc., November 1, 2006; 17(11): 1656 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Kabbinavar, J. Hambleton, R. D. Mass, H. I. Hurwitz, E. Bergsland, and S. Sarkar Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer J. Clin. Oncol., June 1, 2005; 23(16): 3706 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Aapro, C.-H. Kohne, H. J. Cohen, and M. Extermann Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical Trials Oncologist, March 1, 2005; 10(3): 198 - 204. [Abstract] [Full Text] [PDF]
|
|